LA­VA Ther­a­peu­tics winds down bis­pe­cif­ic tri­al; Blue Wa­ter buys six mar­ket­ed drugs for $8.5M

Bis­pe­cif­ic de­vel­op­er LA­VA Ther­a­peu­tics is cut­ting a tri­al for a can­di­date tar­get­ing hema­to­log­i­cal ma­lig­nan­cies af­ter re­view­ing the cur­rent com­pet­i­tive land­scape, choos­ing in­stead to dou­ble down on its sol­id tu­mor pro­gram.

The tri­al be­ing shut­tered was test­ing LA­VA-051 among pa­tients with mul­ti­ple myelo­ma, chron­ic lym­pho­cyt­ic leukemia and acute myeloid leukemia and was orig­i­nal­ly de­signed to en­roll 102 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER